Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00079326 · ClinicalTrials.gov registry record · Phase 2
Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT00079326: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00079326 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00079326, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
This phase II trial is studying how well giving trastuzumab together with ixabepilone works in treating women with HER2-positive metastatic breast cancer. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining trastuzumab with ixabepilone may kill more tumor cells.
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL trastuzumab
- DRUG ixabepilone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2004-01 |
| Est. Completion | 2010-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00079326
The ClinicalTrials.gov registry entry for NCT00079326 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00079326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00079326 about?
NCT00079326 is a clinical study titled "Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer". This phase II trial is studying how well giving trastuzumab together with ixabepilone works in treating women with HER2-positive metastatic breast cancer. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harmi...
What is the current status of trial NCT00079326?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2004-01. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00079326?
The interventions under investigation include: laboratory biomarker analysis (OTHER), trastuzumab (BIOLOGICAL), ixabepilone (DRUG).
Who is sponsoring clinical trial NCT00079326?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.